Produktbild: The Textbook of Kidney Cancer

The Textbook of Kidney Cancer

303,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

01.12.2010

Abbildungen

mit 250 Farbabbildungen, Approx. 250 illus. in color.

Herausgeber

Inderbir S. Gill + weitere

Verlag

Springer

Seitenzahl

768

Maße (L/B)

25,4/17,8 cm

Sprache

Englisch

ISBN

978-1-84882-697-7

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

01.12.2010

Abbildungen

mit 250 Farbabbildungen, Approx. 250 illus. in color.

Herausgeber

Verlag

Springer

Seitenzahl

768

Maße (L/B)

25,4/17,8 cm

Sprache

Englisch

ISBN

978-1-84882-697-7

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: Libri GmbH

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: The Textbook of Kidney Cancer
  • Preface.-History of renal cancer - David Bloom (Michigan) .-Epidemiology and Screening - Joseph K McLaughlin .-Renal Anatomy & Embryology - John Redman (Arkansas) .-Renal Physiology - Martin Schreiber (Cleveland) .-Renal Histology -???.-Pathology: Non-RCC - Eyas M. Hattab (Indiana) .-Pathology: Clear cell - Zhou (CCF), Victor Reuter (NYC) .-Pathology: Non-clear cell (papillar 1 & 2, chromophobe, etc) - Maria Marino (NCI) .-Hypoxia & HIF-related pathways - William Kaelin (Harvard) .-PTEN/mTOR/NFkB pathways - Pantuck (UCLA) .-Tuberous Sclerosis complex (TSC) - Brugarolis (Harvard) .-Familial syndromes - Marston Linehan (NCI) .-VHL mutations - Othon Iliopoulos (Boston) .-Mechanisms of Immunosuppression: Arginase - Ochoa (LSU) .-Mechanisms of Immunosuppression: B7H1, B7H4 - Eugene Kwon (Mayo) .-Mechanisms of Immunosuppression:Immune dysfunction & Tregs - Jim Finke (Cleveland) .-Molecular Genomics - Ben Teh .-Staging systems - Arie Belldegrun (UCLA) .-Prognostic Factors - Chris Wood (Houston) .-Biomarkers: Early detection - Othon Iliopolous (Boston) .-Biomarkers: Prognostic - Fray Marshall (Emory) .-Biomarkers: Expression Profiling - Liberman (Boston) .-Nomograms - Mike Kattan (Cleveland) .-Cystic RCC - Steve Campbell (Cleveland) .-Imaging : Ultrasonography - Jean de la Rosette (Amsterdam) .-Imaging: CT - Ramen (UCLA) .-Imaging: MRI - Rofsky, Pedrosa (Boston) .-Imaging: PET - Shetal Shah (Cleveland) .-Imaging: G250 Monoclonal Antibody - Osterwig (Netherlands) .-Augmented Reality - Osamu Ukimura (Kyoto, Japan) .-Paraneoplastic syndromes - ???? .-Needle Biopsy: current status - Samir Taneja (NYU) .-Pathology of renal biopsy for RCC - Laura Barisoni (NYU) .-Rationale for nephron-sparing - Paul Russo (MSKCC) .-Active surveillance: Pro - Uzzo/Jewett (Fox Chase/Toronto) .-Active Surveillance: Con - Michael Marberger (Austria) .-Open partial nephrectomy: USA - Andrew Novick (Cleveland) .-Open partial nephrectomy: Europe - Joachim Thuroff (Mainz) .-Open partial nephrectomy: non-clamping techniques - Arie Belldegrun (Los Angeles) .-Laparoscopic partial nephrectomy: basics - Ralph Clayman (Irvine) .-Laparoscopic partial nephrectomy: advanced - Inderbir Gill (Cleveland) .-Partial nephrectomy: Extended indications - Bradley Leibovitch (Mayo) .-Complications of partial nephrectomy: open and laparoscopic - Louis Kavoussi (New York) .-Biologic hemostatics and adhesives - Marshall Stoller (San Francisco) .-Renal hypothermia: Basic evidence and contemporary practice - Arieh Shalhav (Chicago) .-Renal cryotherapy: the basics - Steve Nakada (Wisconsin) .-Renal cryotherapy: current status - Inderbir Gill (Cleveland) .-Renal radiofrequency ablation: the basics - Jeffrey Caddedu (Dallas) .-Renal radiofrequency ablation: current status - Gervais/McDougall (Boston) .-Other energy sources: HIFU, inerstitial lasers, photon irradiation - Jamie Landman (New York) .-Extracoroporeal ablation: Radiosurgery - Arul Mahadevan (Cleveland) .-Practice patterns of Surgery for RCC - Brent Hollenbeck (Michigan) .-Level of evidence for NSS - Gordon Muir (London) .-NSS: Overview - Arie Belldegrun/Gill (UCLA/CCF) .-Radical nephrectomy: open - John Fitzpatrick (Dublin) .-Radical nephrectomy: laparoscopic - Clayman (Irvine) .-Cytoreductive nephrectomy: open and laparoscopic - McLellan Walther (NCI) .-Complications of radical nephrectomy: open and laparoscopic - Stuart Wolf (Michigan) .-Angio-infarction - Mark Sands (Cleveland) .-Surgery for locally advanced RCC - Chris Wood (Houston) .-Surgery for pulmonary metastases - Tom Rice (Cleveland) .-Surgery for CNS metastases - Gene Barnett (Cleveland) .-Inferior vena cava thrombi - Michael Blute (Mayo) .-Techniques for venous thrombus surgery - Mark Soloway (Miami) .-Laparoscopic techniques for venous involvement - Alireza Moinzadeh (Syracuse) .-The case for lymphadenectomy - Robert Flanigan (Loyola) .-Concomittant adrenalectomy - Seth Lerner (Houston) .-Use of transplant techniques for wide exposure of the retroperitoneum - Christian Kuhr (Seattle) .-Financial costs of renal surgery - Anoop Meraney (Cleveland) .-Level of evidence for extirpative surgery - Prokar Dasgupta (London) .-Overview of radical surgery - John Libertino (Lahey Clinic) .-Systemic metastases - ??? .-CNS disease - ?? .-Novel uses - ?? .-Surveillance after radical nephrectomy - LAM/Riggs (UCLA) .-Chemotherapy - David Nanus (Cornell) .-IFN - Bukowski, Borden (Cleveland) .-IL-2 - McDermott (Boston) .-Vaccines - Ernstoff (Dartmouth) .-Antibodies - A Jakobowitz (Agensys) .-VEGFR targeted therapy: Sorafenib - Bernard Escudier (Paris) .-VEGFR targeted therapy: Sunitinib - Bob Motzer (NYC) .-VEGF binding agents - Brian Rini (Cleveland) .-Plasma VEGF measurements, VEGF expression, response to treatment - Patard (France) .-Tor Inhibitors - Gary Hudes (Philadelphia) .-Targeted therapy & Immunotherapy combinations - Jared Gollob (Duke) .-Targeted therapy combinations - Keith Flaherty (U Penn) .-Carbonic Anhydrase IX (G250) as target for therapy - Arie Belldegrun (UCLA) .-Treatment of TKI failures - Cho/McDermott (Boston) .-Novel Agents - Bob Figlin (UCLA) .-Selection opportunities - Signoretti (Boston),Pantuck (UCLA) .-Choosing First-line therapy - Brian Rini (Cleveland) .-Treatment of Non-Clear Cell RCC - Walter Stadler (Chicago) .-Neoadjuvant therapy - Eric Jonasch (Houston) .-Adjuvant therapy: Immunotherapy - Chris Wood (Houston) .-Adjuvant therapy: Targeted therapy - Naomi Haas (Philadelphia) .-Palliative therapy - Allan Lipton (Hershey) .-Targeted therapy and Urology practice - Peter Mulder (Netherlands) .-Future directions in renal cancer - Linehan, Belldegrun, Gill, Atkins